Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 53, Issue 10, Pages 4187-4197Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm100265s
Keywords
-
Categories
Funding
- Government of Panama
- Fogarty International Center's International Cooperative Biodiversity Group (ICBG) [ICBG TW006634]
- UCSC
- Panamanian Ministry of Science (SENACYT) [EST06-O-022]
- NSF
Ask authors/readers for more resources
Leishmaniasis is a debilitating disease caused by protozoan parasites of the genus Leishmania, which affects an estimated 12 million people worldwide. The discovery of new lead compounds for leishmaniasis is therefore a pressing concern for global health programs. The organic extract of a Panamanian collection of the marine cyanobacterium Lyngbya majuscula showed strong in vitro activity in two complementary screens against the tropical parasite Leishmania donovani, the causative agent of visceral leishmaniasis. Chromatographic separation of this complex mixture led to the isolation of the highly N-methylated linear lipopeptides, almiramides A-C (1-3). Comparison with the biological activities of a number of related metabolites and semisynthetic derivatives revealed key features required for activity and afforded one new compound (11) with superior in vitro activity. Subsequent synthesis of a library of simplified analogues led to the discovery of several compounds with improved therapeutic indices to the natural products.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available